Patient perspectives on post-operative direct oral anticoagulant for venous thromboembolism prevention in patients with gynecologic cancers undergoing laparotomy

This study aimed to evaluate patient satisfaction during the transition from low molecular weight heparin (LMWH) to direct oral anticoagulant (DOAC) apixaban for extended venous thromboembolism (VTE) prophylaxis in patients with gynecologic cancers undergoing laparotomy. The findings indicated that patients using DOAC reported higher satisfaction, experiencing less difficulty with treatment and lower concerns about medication costs compared to those on LMWH, while maintaining a low incidence of VTE and major bleeding.